Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

This week, the FDA approved AstraZeneca’s AZN Voydeya (danicopan) for a rare blood disorder. Merck’s MRK oral KRAS inhibitor candidate, MK-1084, enters phase III development. Jazz Pharmaceuticals JAZZ completed filing a regulatory https://www.nasdaq.com/articles/pharma-stock-roundup:-azn-voydeya-gets-fda-nod-mrk-kras-inhibitor-enters-phase-iii